Laboratory Monitoring Prior to Starting Baxfendy (Baxdrostat)
You must check serum potassium and renal function (serum creatinine and eGFR) before initiating Baxfendy. 1
Required Baseline Laboratory Tests
According to the FDA prescribing information, the following labs are mandatory prior to starting Baxfendy:
- Serum potassium - Critical given the significant hyperkalemia risk
- Serum creatinine and estimated glomerular filtration rate (eGFR) - Essential for assessing baseline renal function
These tests are explicitly required per the drug label's section on "Testing Prior to and After Initiation of BAXFENDY" 1.
Clinical Context and Rationale
Why These Labs Matter
Hyperkalemia is the primary safety concern with baxdrostat. Meta-analyses consistently demonstrate that baxdrostat increases hyperkalemia risk approximately 5-9 fold compared to placebo 2, 3, 4. Specifically:
- Potassium >5.5 mmol/L occurs in approximately 8.9% of patients (vs 1.2% with placebo) 4
- Potassium >6.0 mmol/L occurs in 3.8% of patients (vs 0.2% with placebo) 4
- The risk ratio for hyperkalemia ranges from 5.59 to 8.64 across studies 2, 5
Renal function monitoring is essential because baxdrostat modestly reduces eGFR (by approximately 5.49 mL/min/1.73 m²) 6. While renal impairment doesn't significantly affect baxdrostat pharmacokinetics and dose adjustment isn't required based on PK differences 7, baseline renal function helps predict hyperkalemia risk and guides monitoring intensity.
Additional Baseline Testing to Consider
While not explicitly mandated by the FDA label for baxdrostat specifically, standard hypertension workup should include 8:
- Serum sodium - Given hyponatremia is listed as a warning 1
- Fasting glucose and lipids - For cardiovascular risk assessment
- 12-lead ECG - Standard for hypertension evaluation
These align with routine testing recommended for any patient with elevated blood pressure or hypertension 8.
Critical Pitfalls to Avoid
Do not start baxdrostat if baseline potassium is already elevated - The drug is contraindicated in hyperkalemia 1
Identify patients on other potassium-raising medications - Concurrent use of ACE inhibitors, ARBs, other MRAs, or potassium supplements dramatically increases hyperkalemia risk 9, 1. These require careful consideration and potentially dose adjustment or discontinuation before starting baxdrostat.
Patients with advanced renal impairment require heightened vigilance - Though dose adjustment isn't required, these patients need more frequent monitoring 9
Discontinue potassium supplements - If the patient is on potassium supplementation for any reason, plan to reduce or stop these within 2-4 days of starting baxdrostat 9
Post-Initiation Monitoring Schedule
For context, after starting baxdrostat, repeat serum electrolytes and renal function within 2-3 months 9, 1. More frequent monitoring (potentially every 2-4 weeks initially) is warranted in patients with:
- Prior severe hypokalemia
- Baseline renal impairment
- Concurrent use of drugs affecting potassium 9